Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Andorra Health Watch.
Press releases published on July 11, 2025
FibroBiologics to Present at the Advanced Wound Care Summit USA
HOUSTON, July 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic …
Jaylen Brown, Abdulla Al Zain & Ahsan Ashraf Join Board to Drive Innovation & Global Expansion; Riz Shah Named Chairman
VANCOUVER, British Columbia, July 11, 2025 (GLOBE NEWSWIRE) -- Hapbee Technologies, Inc. (TSXV: HAPB | OTCQB: HAPBF) (“Hapbee” or the “Company”), a leading wearable wellness technology company, is pleased to announce as an update to its press releases …
Full Alliance Group Obtains FDA MOCRA Registration for HOCl Platform
TAMPA, Fla., July 11, 2025 (GLOBE NEWSWIRE) -- Full Alliance Group Inc. (OTC: FAGI) and its fifty one percent owned subsidiary, Aquaox Pure Solutions, LLC, announce two pivotal regulatory achievements that position the company at the forefront of the …
Creative Medical Technology Holdings Receives Notice of Allowance for ImmCelz™ for Treatment of Heart Failure and/or Post Infarct Pathological Remodeling
PHOENIX, July 11, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company specializing in regenerative medicine, today announced that it has received a …
Evaxion finalizes agreement with EIB to convert debt into equity
Evaxion and the European Investment Bank (EIB) have finalized a debt settlement agreement of €3.5 million out of Evaxion’s €7 million loan with EIB, to be used for EIB to purchase €3.5 million worth of ordinary Evaxion warrants EIB will purchase the …
Cerevance Announces Presentations at the Alzheimer's Association International Conference 2025
Data from the Phase 1 clinical trial of novel KCNK13 inhibitor showed good CNS exposure and was generally well-tolerated Proprietary NETSseq platform explores the key potential role of astrocytes in Alzheimer’s disease BOSTON, July 11, 2025 (GLOBE …
Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025 after the market closes. Company management will host a …
Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders
SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today announced the receipt of a $6 million non-dilutive …
Heartflow Plaque Analysis Awarded First Coverage Recommendation by Radiology Benefits Manager
MOUNTAIN VIEW, Calif., July 11, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc., the leader in AI technology for coronary artery disease (CAD), today announced Heartflow Plaque Analysis will be included in updated cardiac imaging guidelines by radiology benefit …
Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Merger with Inmagene Biopharmaceuticals
BOSTON, July 11, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” the “Company”) today announced that Institutional Shareholder Services Inc. (“ISS”) and Glass, Lewis …
Shareholders of Renergen Limited Approve Proposed Acquisition by ASP Isotopes Inc.
WASHINGTON, July 11, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple …
BriaCell’s Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer
Median Overall Survival (OS) of 13.9 months in triple negative breast cancer (TNBC) exceeds Trodelvy (11.8 months) and doubles control (6.9 months) OS of 17.3 months in HR+ metastatic breast cancer surpasses Trodelvy (14.4 months) and control (11.2 months) …
Zevra Therapeutics Announces MIPLYFFA® (arimoclomol) Featured in Presentations at the National Niemann Pick Disease Foundation Conference
CELEBRATION, Fla., July 11, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced an oral presentation and …
MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer
NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced the publication of another …
Laser Systems and Components Market Sees Strong Global Growth
Boston, July 11, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, the “Global Markets for Laser Systems, Components and Materials" is expected to grow from $21.0 billion in 2024 to reach $30.4 billion by the end of 2029, at a …
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
FDA issued Complete Response Letter Capricor plans to resubmit its BLA to include data from the ongoing Phase 3 HOPE-3 trial in Q3 2025 to continue pursuing the indication for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy FDA …
Milestone Pharmaceuticals Announces Proposed Public Offering
MONTREAL, Quebec and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST) today announced that it has commenced an underwritten public offering (the “Offering”) of its common shares, accompanying …
Milestone Pharmaceuticals Announces FDA Acceptance of the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray
New PDUFA Action Date of December 13, 2025 $75 Million Royalty Purchase Agreement Payment from RTW Extended Through 2025 MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) (Milestone) today …
e-therapeutics reduziert Risiken im klinischen Verfahren für GalOmic-Kandidaten ETX-312 dank positiver Ergebnisse in der vorklinischen Phase
ETX-312 wurde in GLP-konformen Toxikologiestudien in überhöhten Dosierungen gut vertragen GMP-konforme Herstellung einer Charge für klinische Studien erfolgreich abgeschlossen Auf Kurs für die Einreichung bei der CTA im vierten Quartal 2025 LONDON, July 11 …
e-therapeutics sécurise le développement clinique de son candidat GalOmic ETX-312 grâce à des données non cliniques positives
ETX-312 bien toléré à des doses élevées lors d’études de toxicologie conformes aux normes BPL Fabrication du lot destiné à l’essai clinique achevée avec succès conformément aux normes BPF Soumission de la demande d’autorisation d’essai clinique en bonne …